<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562666</url>
  </required_header>
  <id_info>
    <org_study_id>ID RCB 2007-A00249-44</org_study_id>
    <secondary_id>CIC 0203/074</secondary_id>
    <secondary_id>LOC 06/07</secondary_id>
    <nct_id>NCT00562666</nct_id>
  </id_info>
  <brief_title>Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells</brief_title>
  <acronym>ICAR</acronym>
  <official_title>Immunotherapy of Hepatocellular Carcinoma by Hepatic Intra Arterial Injection of Autologous Gamma-delta T Lymphocytes: A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For most patients with hepatocellular carcinoma, surgery or other curative procedures are not
      possible and only palliative measures could be applied (chemoembolization, targeted drugs,
      best supportive cares, etc). In the ICAR study, increasing doses of a cell therapy product
      will be evaluated in patients in a palliative setting. All patients will have one hepatic
      intra-arterial injection of immunological cells (gamma-delta T lymphocytes) and will be
      evaluated for safety.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Onset of: thrombosis of hepatic artery, grade 4 liver toxicity, or grade 3 or more allergic, neurological, dermatological, infectious, or respiratory reaction</measure>
    <time_frame>Within 14 days after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of clinical, biological signs or images evocative of lymphocyte-induced tumor cytotoxicity and/or of a persistence of gamma-delta T cells in peripheral blood. Tumor response will be evaluated with the RECIST criteria.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single hepatic intra arterial administration of 500 millions T gamma delta lymphocytes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single hepatic intra arterial administration of 1000 millions T gamma delta lymphocytes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single hepatic intra arterial administration of 2000 millions T gamma delta lymphocytes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single hepatic intra arterial administration of 4000 millions T gamma delta lymphocytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>T gamma delta lymphocytes</intervention_name>
    <description>Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult over 18

          -  Hepatocellular carcinoma histologically proven, with at least one measurable tumor

          -  Non operable tumor

          -  Alfa foeto protein &gt; 400 ng/ml

          -  Other treatments (surgery, chemoembolization) non indicated

          -  Chemoembolization non indicated due to good performance status (WHO 1) or to tumor
             volume

          -  Performance status WHO &lt; 2

          -  Life expectancy &gt; 3 months

        Non inclusion Criteria:

          -  Extra hepatic metastases

          -  Severe hepatopathy (Child B or C)

          -  Virus B or C chronic hepatitis

          -  Chronic cardiac failure

          -  Uncontrolled severe infectious disease

          -  Other cancer, if not considered as cured

          -  Positive serology for HIV or HTLV

          -  Leucocytes &lt; 3000/mm3 or neutrophils &lt; 1500/mm3

          -  Platelets &lt; 80000/mm3

          -  Serum creatinine &gt; 110 µmol/L

          -  Bilirubin &gt; 35 µmol/L

          -  AST, ALT, alkaline phosphatase &gt; 5N

          -  Current immunosuppressive treatment

          -  Impossibility to comply with scheduled follow-up

          -  Anatomical situation not permitting the selective injection of the product of cell
             therapy

          -  Pregnant or breastfeeding woman, or not using adequate effective contraceptive method

        Exclusion Criterion:

          -  Insufficient number of gamma delta lymphocytes after expansion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc RAOUL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRLCC Eugène Marquis, Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric BELLISSANT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité de Thérapie Cellulaire, Laboratoire de Cytogénétique et Biologie Cellulaire, CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département d'Oncologie Médicale - CRLCC Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirugie Viscérale - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cell therapy</keyword>
  <keyword>T lymphocytes</keyword>
  <keyword>hepatic intra-arterial injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

